TNF and colitis: Another study tested the efficacy of a monoclonal anti-mature IL-18 antibody in DSS colitis mice found that it improved acute and chronic DSS colitis, reduced production of IFNγ and TNFα and ameliorated the epithelial cell barrier (17).